Track topics on Twitter Track topics that are important to you
Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for RoACTEMRA (tocilizumab) for the treatment of polyarticular juvenile idiopathic arthritis (PJIA) in patients two years of age or older who have responded inadequately to previous treatment with methotrexate (MTX). RoACTEMRA, known as ACTEMRA outside Europe, can be given alone or in combination with MTX in people with PJIA.NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Arthritis is by definition the inflammation of one or more joints, characterized by swelling, pain, warmth, redness and diminished range of joint movement (Oxford Medical Dictionary). There are many different types; Noninflammatory; Osteoarthritis, N...